{"version":1,"type":"story","url":"https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools","json":"https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools.json","markdown":"https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools.md","slug":"tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools","headline":"Tempus AI wins FDA clearance for two AI-ECG tools","summary":"**Tempus AI** announced FDA clearance for two AI-powered ECG tools in October 2026, targeting undiagnosed heart conditions. The **Tempus ECG-MR** detects moderate or severe mitral regurgitation from standard 12-lead ECGs, while **Tempus ECG-PH** flags pulmonary hypertension with binary results. Both tools expand Tempus’s cardiovascular AI portfolio amid a market projected to grow from **$2.01 billion in 2025 to $2.40 billion in 2026**, per Business Research, at a **19.3% CAGR**.\n\nThe clearances follow **510(k) approvals**, a regulatory pathway for lower-risk medical devices. Tempus’s stock has fallen **17.7%** over the past year, outpacing the industry’s **10.4%** decline, and trades at a **7.3x forward P/S ratio**, above the industry average of **4.82x**. Competitors like **GE Healthcare** and **iRhythm** also advance AI-ECG tools, with iRhythm reporting **85% accuracy** in pilot programs for arrhythmia detection.","keyPoints":["Tempus AI wins FDA clearance for two AI-ECG tools: Tempus ECG-MR and Tempus ECG-PH","Market size for AI-ECG analysis grows from $2.01B in 2025 to $2.40B in 2026 at 19.3% CAGR","Tempus stock down 17.7% year-over-year, trading at 7.3x forward P/S ratio"],"whyItMatters":"FDA-cleared AI-ECG tools could improve early detection of heart conditions, reducing missed diagnoses and healthcare costs. Tempus’s move accelerates competition in a fast-growing market, but its valuation gap may limit investor confidence.","category":{"slug":"enterprise","name":"Enterprise & Industry","url":"https://digestai.news/category/enterprise"},"entities":{"companies":["Tempus AI","GE Healthcare","iRhythm Holdings"],"models":[],"people":[]},"firstPublishedAt":"2026-10-05T07:03:00Z","updatedAt":"2026-10-05T07:03:00Z","sourceCount":1,"hasPrimarySource":false,"sources":[{"outlet":"finance.yahoo.com","title":"Here's How Tempus AI is Capitalizing on AI-ECG Market Growth","url":"https://finance.yahoo.com/healthcare/articles/heres-tempus-ai-capitalizing-ai-140300775.html","publishedAt":"2026-10-05T07:03:00Z","type":"press","primary":false,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"Tempus AI wins FDA clearance for two AI-ECG tools\", 5 October 2026, https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools","publisher":"Digest AI","title":"Tempus AI wins FDA clearance for two AI-ECG tools","datePublished":"2026-10-05T07:03:00Z","url":"https://digestai.news/story/tempus-ai-wins-fda-clearance-for-two-ai-ecg-tools"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}